他克莫司药效学研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (1): 90-95.

他克莫司药效学研究进展

杨梦^1,2, 左笑丛^1,2, 汪江林^1,2, 陈清洁^1,2

¹中南大学湘雅三医院药学部,长沙 410013,湖南;
²中南大学药学院,长沙 410013,湖南

收稿日期:2013-01-04 修回日期:2014-01-09 出版日期:2014-01-27 发布日期:2014-02-12
通讯作者: 左笑丛,女,副教授,研究生导师,研究方向:临床药学。Tel: 0731-88618458 E-mail: zuoxc08@126.com
作者简介:杨梦,女,硕士研究生,研究方向:临床药学。Tel: 15273138598 E-mail: yangmjy@yeah.net
基金资助:
国家自然科学基金资助项目(81102512);教育部博士点基金资助项目(20110162120023);重大基础研究前期研究专项(937前期专项)(2011CB512001);湖南省卫生厅资助课题(B2010-034);新世纪优秀人才支持计划(NCET-12-0605)

Advance in study on tacrolimus pharmacodynamics

YANG Meng^1,2, ZUO Xiao-cong^1,2,WANG Jiang-lin^1,2,CHEN Qing-Jie^1,2

¹Department of Pharmacy, the Third Xiangya Hospital, Certral South University, Changsha 410013,Hunan,China;
²School of Pharmaceutical Science, Central South University, Changsha 410013, Hunan,China

Received:2013-01-04 Revised:2014-01-09 Online:2014-01-27 Published:2014-02-12

摘要/Abstract

摘要： 他克莫司是一种钙调磷酸酶抑制剂,主要是通过抑制T细胞活化相关细胞因子(IL-2、IL-3、IL-4、IL-5、IFN-γ、TNF-α、GM-CSF)的转录和IL-2、IL-7受体的表达发挥免疫抑制作用。此外,临床及动物实验中均显示他克莫司在预防及治疗器官移植排斥反应方面效果显著。主要不良反应为肾毒性、神经毒性、高血压、糖尿病、牙龈增生等。

关键词: 他克莫司, 药效学, 细胞因子, 排斥反应, 不良反应

Abstract: Tacrolimus is a kind of calcineurin inhibitor, mainly suppressing the transcription of cytokines IL-2, IL-3, IL-4, IL-5, IFN-γ, TNF-α, GM-CSF and expression of IL-2, IL-17 receptor. In addition, tacrolimus shows remarkable immunosuppressive effects in the prevention and treatment of organ transplant rejection in clinical and animal experiments. Its major adverse reaction includes nephrotoxicity, neurotoxicity, hypertension, posttransplantation diabetes mellitus,gingival hyperplasia, and so on.

Key words: Tacrolimus, Pharmacodynamics, Cytokine, Rejection, Side effect

中图分类号:

杨梦, 左笑丛, 汪江林, 陈清洁. 他克莫司药效学研究进展[J]. 中国临床药理学与治疗学, 2014, 19(1): 90-95.

YANG Meng, ZUO Xiao-cong,WANG Jiang-lin,CHEN Qing-Jie. Advance in study on tacrolimus pharmacodynamics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 90-95.

参考文献

[1] Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J]. Clin Ther, 2002, 24(3):330-350.
[2] Dambrin C, Klupp J, Morris RE.Pharmacodynamics of immunosuppressive drugs[J].Curr Opin Immunol , 2000, 12(5):557-562.
[3] El-Safa EA, Fredericks S, MacPhee I,et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression [J]. Transplant Proc,2006,38(10):3327-3330.
[4] Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression[J]. Cell Prolif,2007,40(1):50-63.
[5] Ke H, Huai Q. Structures of calcineurin and its complexes with immunophilins-immunosuppressants[J]. Biochem Biophys Res Commun, 2003, 311(4):1095-1102.
[6] Migita K, Eguchi K. FK506-mediated T-cell apoptosis induction[J]. Transplant Proc,2001 ,33(3):2292-2293.
[7] Choi SJ, You HS, Chung SY. Tacrolimus-Induced Apoptotic Signal Transduction Pathway[J]. Transplant Proc, 2008, 40 (8):2734-2736.
[8] Satoshi M, Futoshi S, Kenji T, et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation[J].EMBO, 2000, 1(5):428-434.
[9] 何懿,李民,刘占国,等.他克莫司对全血细胞因子分泌的影响[J].南方医科大学学报,2010,30(2):249-251.
[10] Liu ZG, Yuan XP, Luo YW, et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood[J].Cytokine, 2009, 45 (2):141-147.
[11] Wei HY, Pan W, Qiu N, et al. High concentration of tacrolimus inhibits proliferation and osteoblastic differentiation of human mesenchymal stem cells[J].Chin J Pharmacol Toxicol, 2011, 25(3): 223-228.
[12] Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients[J]. Clin Transplant, 1999, 13(5): 400-409.
[13] Jamie LM , Ericson SG. Cyclosporin A and Tacrolimus (FK506) differentially alter T-cell receptor expression in vivo[J].Immunopharm Immunot, 2007,29(1):105-118.
[14] 白杨娟,王兰兰,蔡蓓,等.他克莫司与环孢菌素A对肝移植受者CD4/CD8T淋巴细胞亚群及共刺激分子的调节作用[J].细胞与分子免疫学杂志,2008,24(10):989-992.
[15] Wu CS, Lan CC, Kuo HY,et al. Differential regulation of nuclear factor-kappa B subunits on epidermal keratinocytes by ultraviolet B and tacrolimus[J]. Kaohsiung J Med Sci, 2012, 28(11):577-585.
[16] 孙君重,肖文华,于力.CD₄⁺ T淋巴细胞功能研究新进展[J].中国实验血液学杂志,2010,18(2):544-548.
[17] 郭业磊,陈钰.CD8⁺ T调节细胞的研究进展[J]. 细胞与分子免疫学杂志,2009,25(8):762-763.
[18] 李佳,白杨娟,王兰兰,等.FK506对肝移植受者T细胞亚群上CD152和PD-1的调节研究[J].细胞与分子免疫学杂志,2008,24(1):54-57.
[19] Claudia S, Martin Z, Stefan M, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-Treated kidney transplant recipients[J].Transplantation, 2010, 89 (11):1417-1423.
[20] Cheung CY, Chan HW, Liu YL, et al. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis[J].Nephrology , 2009,14(8):758-763.
[21] Mizuiri S, Iwamoto M, Miyagi M, et al. Activation of nuclear factor-kappa B and macrophage invasion in cyclosporin A and tacrolimus-treated renal transplants[J]. Clin Transplant, 2004, 18(1): 14-20.
[22] Hymes LC, Warshaw BL. Tacrolimus rescue therapy for children with acute renal transplant rejection[J]. Pediatr Nephrol, 2001, 16(12):990-992.
[23] Demirci MS, Toz H, Ylmaz F, et al. Risk factors and consequences of post-transplant diabetes mellitus[J]. Clin Transplant, 2010,24(5): 170-177.
[24] Ochiai T, Nakajima K, Nagata M, et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allo-transplantation in rats[J]. Transplantation, 1987, 44(6): 734 -738.
[25] Moriuchi H, Kamohara Y, Eguchi S,et al. Diverse effects of FK506 on the apoptosis of hepatocytes and infiltrating lymphocytes in an allografted rat liver[J]. J Surg Res, 2011,167(1):131-139.
[26] 魏思东,龚建平,李金政,等. 他克莫司通过抑制GITRL减轻大鼠肝移植排斥反应的研究[J].南方医科大学学报,2011,31(9):1480-1483.
[27] Jiang H, Yang XF, Wynn C, et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection[J]. Transplant Proc, 2001, 33(1/2):510-513.
[28] Zhu L, Hua ZH, Song HT. Pharmacogenomics and personalized medicine of tacrolimus[J].Chin J Clin Pharmacol Ther,2011, 16(6): 710-750.
[29] Pech T, Fujishiro J, Finger T,et al. Effects of immunesuppressive therapy after experimental small bowel transplantation in rats[J]. Transpl Immunol, 2011, 25(2/3) : 112-118.
[30] Qi XM , Wu YG, Liang C,et al. FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin [J]. Int Immunopharmacol, 2011,11(10):1613-1619.
[31] Justo P, Lorz C, Sanz A , et al. Intracellular mechanisms of cyclosporine A-induced tubular cell apoptosis[J].Am Soc Nephrol, 2003, 14(12):3072-3080.
[32] Yang CW, Faulkner GR, Wahba IM, et al. Expression of apoptosis related genes in chronic cyclosporine nephrotoxicity in mice[J]. Am J Transplant, 2002,2(5) :391- 399.
[33] Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine associa ted interstitialfi brosis[J]. Kidney Int,1998, 53(4) :897- 908.
[34] Shihab FS, Andoh TF, Tanner AM, et al. Expression of apoptosis regulatory genes in chronic cyclospori ne nephrotoxicity favors apoptosis[J]. Kidney Int, 1999,56(6):2147-2159.
[35] Ewout JH, Walsh SB, McCormick JA,et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension[J]. Nat Med,2012, 17(10): 1304-1309.
[36] Chiasson VL, Talreja D, Yong KJ, et al. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension[J].Hypertension, 2011,57(6):1167-1175.
[37] Rauch MC, San Martín A, Ojeda D, et al. Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects[J]. Transpl Immunol,2009, 22(1/2): 72-81.
[38] Khoury N, Kriaa F, Hiesse C,et al. Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression[J].Transplant Pro,2000, 32(8):2763-2764.
[39] Chiasson VL, Jones KA, Kopriva SE,et al. Endothelial cell trans-forming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis[J].Kidney Int,2012,82(8):1-10.
[40] De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients[J]. Clin J Am Soc Nephrol,2011,6(3): 690 - 694.
[41] 陈斌,马爱民,林建群.他克莫司的不良反应[J].海峡药学,2007,19(10):130-131.
[42] Ruth AL ,Steven G. Current trends in immunosuppressive therapies for renal transplant recipients [J]. Am J Health-Syst Pharm, 2012,69 (15):1961-1975.
[43] 龚丽娴,袁进.他克莫司致高钾血症1例[J].医药导报,2012,6(31):705.